Treatment of Non-Small-Cell Lung Cancer with Erlotinib following Gefitinib-Induced Hepatotoxicity : Review of 8 Clinical Cases
المؤلفون المشاركون
Yokota, Soichiro
Mori, Masahide
Kagami, Shinichi
Namba, Yoshinobu
Nakazawa, Yukie
Yano, Yukihiro
Kimura, Hiromi
Yoneda, Tsutomu
Niinaka, Manabu
Yamaguchi, Toshihiko
Nashi, Ayumi
المصدر
العدد
المجلد 2012، العدد 2012 (31 ديسمبر/كانون الأول 2012)، ص ص. 1-6، 6ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2012-11-08
دولة النشر
مصر
عدد الصفحات
6
التخصصات الرئيسية
الملخص EN
Objective.
Gefitinib often induces liver damage.
A few reports have described that the subsequent administration of erlotinib was associated with less hepatotoxicity, but the safety and efficacy of this treatment are still not fully investigated.
Therefore, we evaluated retrospectively the patients with erlotinib following gefitinib-induced hepatotoxicity.
Methods and Patients.
We retrospectively reviewed the medical records between December 2007 and March 2010.
The patients were evaluated including the following information: age, gender, histology of lung cancer, performance status, smoking status, epidermal growth factor receptor (EGFR) mutation status, liver metastasis, viral hepatitis, alcoholic liver injury, clinical response, and hepatotoxicity due to EGFR tyrosine kinase inhibitors.
Results.
We identified 8 patients with erlotinib following gefitinib-induced hepatotoxicity.
All achieved disease control by gefitinib.
Hepatotoxicity was grades 2 and 3 in 3 and 5 patients, respectively.
The median duration of treatment with gefitinib was 112.5 days and the median time to gefitinib-induced hepatotoxicity was 51.5 days.
The median duration of treatment with erlotinib was 171.5 days.
Grade 1 and 2 erlotinib-induced hepatotoxicity was observed in 2 and 1 patient, respectively.
Conclusions.
Erlotinib administration with careful monitoring is thought to be a good alternative strategy for patients who respond well to gefitinib treatment but experience hepatotoxicity.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Yano, Yukihiro& Namba, Yoshinobu& Mori, Masahide& Nakazawa, Yukie& Nashi, Ayumi& Kagami, Shinichi…[et al.]. 2012. Treatment of Non-Small-Cell Lung Cancer with Erlotinib following Gefitinib-Induced Hepatotoxicity : Review of 8 Clinical Cases. Lung Cancer International،Vol. 2012, no. 2012, pp.1-6.
https://search.emarefa.net/detail/BIM-465324
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Yano, Yukihiro…[et al.]. Treatment of Non-Small-Cell Lung Cancer with Erlotinib following Gefitinib-Induced Hepatotoxicity : Review of 8 Clinical Cases. Lung Cancer International No. 2012 (2012), pp.1-6.
https://search.emarefa.net/detail/BIM-465324
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Yano, Yukihiro& Namba, Yoshinobu& Mori, Masahide& Nakazawa, Yukie& Nashi, Ayumi& Kagami, Shinichi…[et al.]. Treatment of Non-Small-Cell Lung Cancer with Erlotinib following Gefitinib-Induced Hepatotoxicity : Review of 8 Clinical Cases. Lung Cancer International. 2012. Vol. 2012, no. 2012, pp.1-6.
https://search.emarefa.net/detail/BIM-465324
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-465324
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر